Nayla Majeda Alfarafisa

Dr. Nayla Majeda Alfarafisa

Universitas Padjadjaran, Bandung, Jawa Barat, Indonesia
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2023 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
YCYoan Chou
Yoan Chou
NANayla Majeda Alfarafisa
Nayla Majeda Alfarafisa
MIMaiko Ikezawa
Maiko Ikezawa
AKAstrid Feinisa Khairani
Astrid Feinisa Khairani
Introduction: The skin is a vital organ as the body’s largest barrier, but its function declines with aging. Therefore, research into effective regeneration treatments must continue to advance. Stem cell transplantation, a cell-based therapy, has become a popular skin-aging treatment, although it comes with drawbacks like host immune reactions. Stem cell-derived cell-free therapies have emerged as an alternative, backed by promising preclinical findings. Stem cell secretomes and extracellular vesicles (EVs) are the key components in cell-free therapy from stem cells. However, comprehensive reviews on the mechanisms of such treatments for skin aging are still limited. Purpose: This review discusses stem cell-derived cell-free therapy’s potential mechanisms of action related to skin aging prevention by identifying specific molecular targets suitable for the interventions. Methods: A search identified 27 relevant in vitro studies on stem cell-derived cell-free therapy interventions in skin aging model cells without restricting publication years using PubMed, Scopus, and Google Scholar. Results: Stem cell-derived cell-free therapy can prevent skin aging through various mechanisms, such as (1) involvement of multiple regenerative pathways [NFkb, AP-1, MAPK, P-AKT, NRF2, SIRT-1]; (2) oxidative stress regulation [by reducing oxidants (HO-1, NQO1) and enhancing antioxidants (SOD1, CAT, GP, FRAP)]; (3) preventing ECM degradation [by increasing elastin, collagen, HA, TIMP, and reducing MMP]; (4) regulating cell activity [by reducing cell senescence (SA-β-gal), apoptosis, and cell cycle arrest (P53, P12, P16); and enhancing autophagy, cell migration, and cell proliferation (Ki67)] (5) Regulating the inflammatory pathway [by reducing IL-6, IL-1, TNF-⍺, and increasing TGF-β]. Several clinical trials have also revealed improvements in wrinkles, elasticity, hydration, pores, and pigmentation. Conclusion: Stem cell-derived cell-free therapy is a potential novel treatment for skin aging by cell rejuvenation through various molecular mechanisms.

27 July 2022 in Cells
Verified
Journal Article
Open access
PDF file
MTMarselina Irasonia Tan
Marselina Irasonia Tan
NANayla Majeda Alfarafisa
Nayla Majeda Alfarafisa
PSPopi Septiani
Popi Septiani
ABAnggraini Barlian
Anggraini Barlian
MFMochamad Firmansyah
Mochamad Firmansyah
HNHusna Nugrahapraja
Husna Nugrahapraja
Since it was first reported, the novel coronavirus disease 2019 (COVID-19) remains an unresolved puzzle for biomedical researchers in different fields. Various treatments, drugs, and interventions were explored as treatments for COVID. Nevertheless, there are no standard and effective therapeutic measures. Meanwhile, mesenchymal stem cell (MSC) therapy offers a new approach with minimal side effects. MSCs and MSC-based products possess several biological properties that potentially alleviate COVID-19 symptoms. Generally, there are three classifications of stem cell therapy: cell-based therapy, tissue engineering, and cell-free therapy. This review discusses the MSC-based and cell-free therapies for patients with COVID-19, their potential mechanisms of action, and clinical trials related to these therapies. Cell-based therapies involve the direct use and injection of MSCs into the target tissue or organ. On the other hand, cell-free therapy uses secreted products from cells as the primary material. Cell-free therapy materials can comprise cell secretomes and extracellular vesicles. Each therapeutic approach possesses different benefits and various risks. A better understanding of MSC-based and cell-free therapies is essential for supporting the development of safe and effective COVID-19 therapy.

1 May 2025 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
NANayla Majeda Alfarafisa
Nayla Majeda Alfarafisa
YCYoan Chou
Yoan Chou
RSResti Santika
Resti Santika
BRBetha Egih Riestiano
Betha Egih Riestiano
HSHardisiswo Soedjana
Hardisiswo Soedjana
MSMas Rizky Aa Syamsunarno
Mas Rizky Aa Syamsunarno
Introduction: Pathological scars, including hypertrophic, keloid, and atrophic scars, remain challenging to treat, with current therapies offering limited success. Adipose-derived stem cell (ADSC) products, classified into cell-based therapies (stromal vascular fraction [SVF], ADSCs) and cell-free therapies (adipose tissue extract [ATE], secretomes, exosomes, extracellular vesicles), have emerged as potential treatments. Purpose: This review examines the therapeutic potential of ADSC products for pathological scars in preclinical and clinical trials, aiming to bridge the gap between experimental research and clinical application. The effectiveness of ADSC products as monotherapies and in combination with other treatments has also been explored. Methods: A comprehensive literature search followed the PICO framework, utilizing electronic databases such as PubMed and Scopus. Original research articles, including both preclinical and clinical trials, were included. Results: This review included 43 studies that demonstrated the potential of ADSC products to improve pathological scars. ADSC products improve scar texture by regulating ECM, promoting adipogenesis and angiogenesis, and reducing inflammation in hypertrophic and keloid scars. In addition, ADSC products also prevented collagen degradation in atrophic scars. Although their effectiveness varied, ADSC products also showed potential when combined with treatments such as fractional CO2 laser, PRP, botulinum toxin, and photo-modulation. Conclusion: ADSC products show promise in treating pathological scars, with varying effectiveness in monotherapy or combination therapy.

1 January 2025 in Breast Cancer: Targets and Therapy
Verified
Journal Article
Open access
PDF file
AKAstrid Feinisa Khairani
Astrid Feinisa Khairani
SHShella Harmonia
Shella Harmonia
YCYoan Chou
Yoan Chou
NANayla Majeda Alfarafisa
Nayla Majeda Alfarafisa
JRJulia Ramadhanti
Julia Ramadhanti
Purpose: The high mortality rate of breast cancer motivates researchers to search for effective treatments. Due to their ability to simulate human conditions, xenograft models such as CDX (Cell line-Derived Xenografts) and PDX (Patient-Derived Xenografts) have gained popularity in pre-clinical research. The choice of xenograft technique is influenced by the type of tumor employed, particularly in more aggressive tumor models like TNBC with metastases. Subcutaneous or orthotopic implantation may influence tumor engraftment rates and the applicability of the models for drug testing. To optimize xenograft models and support the development of breast cancer drugs, selecting a suitable transplantation technique is essential to attaining the best results. Methods: This scoping review used PRISMA-Scr methodology to summarize findings from eleven articles published between 2012 and 2024 on pre-clinical trials related to xenograft models for breast cancer considering PDX began traction after 2010. Using specific criteria, the review included studies from electronic platforms. The inclusion criteria ensured relevant English sources were available in full text, while the exclusion criteria eliminated certain types of articles and inadequately comprehensive studies. Results: Subcutaneous and orthotopic implantation are critical methods for xenograft models in cancer research. Subcutaneous implantation is less invasive and more manageable but does not fully mimic the tumor’s natural environment. Orthotopic implantation accurately mimic the migration, invasion, and molecular characteristics of the original tumor, although the procedure is more complex and requires specialized techniques. The specific research objectives determine their choice, the need for accurate tumor replication, and the testing convenience. Conclusion: Orthotopic implantation is the preferable method for developing PDX and CDX models of breast cancer because it closely mimics the tumor microenvironment and metastatic behavior, yielding clinically relevant results for drug testing. Subcutaneous implantation may result in higher engraftment rates, but it cannot accurately represent the complexity of tumors.

1 February 2024 in Advances and Applications in Bioinformatics and Chemistry
Verified
Journal Article
Open access
PDF file
HWhesti lina wiraswati
hesti lina wiraswati
MBMuhammad Hasan Bashari
Muhammad Hasan Bashari
NANayla Majeda Alfarafisa
Nayla Majeda Alfarafisa
IMIlma Fauziah Ma’ruf
Ilma Fauziah Ma’ruf
ESEti Nurwening Sholikhah
Eti Nurwening Sholikhah
EDEma Damayanti
Ema Damayanti
Background: Multidrug resistance in various cancer types is a major obstacle in cancer treatment. The concept of a single drug molecular target often causes treatment failure due to the complexity of the cellular processes. Therefore, combination chemotherapy, in which two or more anticancer drugs are co-administered, can overcome this problem because it potentially have synergistic efficacy besides reducing resistance, and drug doses. Previously, we reported that pyrazoline B had promising anticancer activity in both in silico and in vitro studies. To increase the efficacy of this drug, co-administration with established anticancer drugs such as doxorubicin and paclitaxel is necessary. Materials and Methods: In this study, we used an in silico approach to predict the synergistic effect of pyrazoline B with paclitaxel or doxorubicin using various computational frameworks and compared the results with those of an established study on the combination of doxorubicin-cyclophosphamide and paclitaxel-ascorbic acid. Results and Discussion: Drug interaction analysis showed the combination was safe with no contraindications or side effects. Furthermore, molecular docking studies revealed that doxorubicin-pyrazoline B and doxorubicin-cyclophosphamide may synergistically inhibit cancer cell proliferation by inhibiting the binding of topoisomerase I to the DNA chain. Moreover, the combination of pyrazoline B-paclitaxel may has synergistic activity to cause apoptosis by inhibiting Bcl2 binding to the Bax fragment or inhibiting cell division by inhibiting α-β tubulin disintegration. Paclitaxel-ascorbic acid had a synergistic effect on the inhibition of α-β tubulin disintegration. Conclusion: The results show that this combination is promising for further in vitro and in vivo studies.

1 July 2023 in Journal of Pharmacy & Pharmacognosy Research
Verified
Journal Article
Open access
HWhesti lina wiraswati
hesti lina wiraswati
MBM. Hasan Bashari
M. Hasan Bashari
NANayla Majeda Alfarafisa
Nayla Majeda Alfarafisa
IMIlma Fauziah Ma'ruf
Ilma Fauziah Ma'ruf
ESEti Nurwening Sholikhah
Eti Nurwening Sholikhah
EDEma Damayanti
Ema Damayanti
J. Pharm. Pharmacogn. Res., vol. 11, no. 4, pp. 699-713, Jul-Aug 2023. DOI: https://doi.org/10.56499/jppres23.1591_11.4.699 Original Article Virtual screening of anticancer activity of chalcones and pyrazolines as potential EGFR, VEGFR, and cytochrome P450 inhibitors [Detección virtual de la actividad anticancerígena de las chalconas y las pirazolinas como posibles inhibidores de EGFR, VEGFR y citocromo P450] Hesti Lina Virtual screening of anticancer activity of chalcones and pyrazolines as potential EGFR, VEGFR, and cytochrome P450 inhibitors.